Case Of Gastritis Research Articles

Carbimazole-induced eosinophilic gastroenteritis in a young female with abdominal pain and ascites: a case report

BackgroundEosinophilic gastroenteritis is a rare disease characterized by eosinophilic infiltration into one or more layers of the gastrointestinal tract. It commonly affects children more than adults. The clinical features depend on the site of gut involvement, but the most common symptoms include abdominal pain and diarrhea. The most common cause reported in the literature is hypersensitivity, as many patients have a history of seasonal allergies, atopy, asthma, food allergies, and so on. However, drugs can be a rare triggering factor. In the literature review, we found multiple case reports of eosinophilic gastroenteritis; however, only one other case of carbimazole-induced eosinophilic gastritis has been reported.Case presentationWe report herein the case of a 36-year-old female from the Philippines who developed eosinophilic gastroenteritis localized to the esophagus and ileum 12 months following treatment with carbimazole for hyperthyroidism. In our facility, she was extensively investigated for malignancy, autoimmune pathologies and infectious etiologies. As the symptoms coincided with carbimazole exposure and other causes were ruled out, we labeled her as carbimazole-induced eosinophilic gastroenteritis. On subsequent follow-up after discharge, her symptoms and eosinophilia resolved when carbimazole was discontinued, suggesting a causative role. This is the first case of eosinophilic gastroenteritis secondary to carbimazole encountered in our region.ConclusionDiagnosis of eosinophilic gastroenteritis requires three criteria, namely (1) presence of gastrointestinal symptoms, (2) histologic evidence of eosinophilic infiltration in one or more areas of the gastrointestinal tract, and (3) exclusion of other causes of tissue eosinophilia. Our patient fulfilled all the criteria; additionally, she had a positive history of atopic tendencies and drug exposure. The diagnosis of hyperthyroidism was established a year ago and in another facility, so we were not sure of the underlying etiology of hyperthyroidism. Upon subsequent follow-up, her thyroid function remained stable. The case highlights the need for a collaborative multidisciplinary approach toward managing rare conditions.

A case of Russell body gastritis associated with psychiatric disorder

Abstract Introduction/Objective Russell body gastritis is a benign and rare entity characterized by infiltration of lamina propria with plasma cells stuffed with spherical eosinophilic cytoplasmic inclusions known as Russell bodies which represent immunoglobulins. Russell bodies accumulate due to dysfunction in secretion pathway of plasma cells. Plasma cells with Russell bodies are also termed Mott cells. Although exact etiology is unknown, but it can be seen in association with other conditions like mucosa associated lymphoid tissue (MALT) lymphoma, multiple myeloma and plasmacytoma. This condition most commonly affects the antrum and may present as erythema or sometimes nodular lesion. Definitive diagnosis is based on histology. Methods/Case Report A middle-aged male with past medical history significant for polysubstance use disorder, bipolar disorder, and osteoarthritis was evaluated for bleeding per rectum and dyspepsia in the setting of chronic nonsteroidal anti-inflammatory drugs (NSAID) and ethanol use. Physical examination was remarkable for an external hemorrhoid and complete blood count showed anemia. Upper GI endoscopy and colonoscopy was performed. Patchy erythema was seen in antrum and duodenal bulb, and colonoscopy was unremarkable. Microscopic examination showed numerous plasma cells with Russell bodies (Mott cells) in the lamina propria and mild chronic inflammation in gastric mucosa. H. Pylori was negative by immunohistochemistry (IHC). Plasma cells were polyclonal and positive for CD138, and negative for cytokeratin which excluded plasmacytoma and signet-ring adenocarcinoma, respectively. Patient was placed on proton pump inhibitor therapy and discharged. Results (if a Case Study enter NA) Russell body gastritis can be seen in patients with and without H. Pylori infection. Cytokeratin, kappa and lambda immunohistochemistry stains, and gene rearrangement studies may be needed to exclude frequent lesions that may enter in the differential diagnosis. Long term effects and clinical significance of russell bodies accumulation is yet to be determined. Conclusion Russell body gastritis is a rare morphologic variant of chronic gastritis that may enter in the differential diagnosis with other more serious lesions. A careful morphologic examination and occasionally IHC stains / molecular studies are needed to make the correct diagnosis.

Prospective Randomized Study Comparing the Outcomes of Single Anastomosis Sleeve Jejunal Bypass (SAS-J) with One Anastomosis Gastric Bypass (OAGB)

Abstract Background One Anastomosis Gastric Bypass is one of the commonest bariatric surgeries worldwide, which has been demonstrated to produce excellent bariatric and metabolic outcomes. Single Anastomosis Sleeve Jejunal Bypass is a novel procedure that was developed in Hazrat e Rasool Hospital by Pazouki and Kermansavari in 2019 to form an anastomosis between the sleeved stomach and the jejunum rather than the ileum as a modification of the previously known SASI. Objective To compare the outcome of SASJ with OAGB as regards efficacy and safety in a 6- month postoperative follow up period. Patients and Methods This was a comparative prospective randomized study conducted in Ain Shams University Hospitals, over 40 patients devided into 2 groups. First group was composed of 20 patients who underwent SASJ operation, and second group was composed of 20 patients who underwent OAGB operation. Results The mean excess weight loss percentage after 6 months of SASJ group of patients was 51.55% ± 15.11, and 58.30% ± 24.32 in OAGB group. Both groups showed excellent outcomes as regards comorbidities resolution. In OAGB group, there was 1 patient who had postoperative bleeding. In SASJ group, we had one case of reflux alkaline gastritis that needed readmission. In addition, we had one case (5%) that needed reoperation and conversion to Roux-en Y configuration. In SASJ group, there were 7 patients complained from bile reflux, and 3 patients in OAGB group. In SASJ group of patients we had only 1 patient who developed postoperative gall bladder stones, and 6 patients in OAGB group. Conclusion Both OAGB and SASJ are effective bariatric procedures as regards weight loss and comorbidities resolution such as DM, HTN and hyperlipidemia. Incidence of biliary reflux was found more among the SASJ patients, but it was almost overcomed after performing the antireflux suture.

S5106 A Rare Case of Non-pylori Helicobacter Gastritis from Feline Mouth-to-Mouth CPR

S5106 A Rare Case of Non-pylori Helicobacter Gastritis from Feline Mouth-to-Mouth CPR

S5103 A Rare Case of Collagenous Gastritis, Enteritis, and Colitis in an Elderly Female

S5103 A Rare Case of Collagenous Gastritis, Enteritis, and Colitis in an Elderly Female

S5178 A Rare Case of Collagenous Gastritis in Patient Presenting With Gastric Perforation

S5178 A Rare Case of Collagenous Gastritis in Patient Presenting With Gastric Perforation

A case of gastritis caused by immune checkpoint inhibitor treated with infliximab.

Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) in various organs. Herein, we present a rare case involving a patient with immunotherapy-related gastritis who developed refractory vomiting and anorexia after treatment with nivolumab for cutaneous malignant melanoma. The patient was treated with oral corticosteroids, but the efficacy was limited. The symptoms improved markedly after treatment with infliximab. With the increasing use of ICIs, the number of reports of gastritis due to irAEs has also increased. Health care providers treating malignancies should be aware of this side effect and know how to diagnose and treat it.

Routine Histopathology in Laparoscopic Sleeve Gastrectomy Over 10 Years.

Laparoscopic sleeve gastrectomy (LSG) is one of the world's most commonly performed types of bariatric surgery. Routine histopathology of the surgical specimen is undertaken at most institutions, regardless of the lack of clinical suspicion of any sinister pathology. We evaluated the histopathology reports of LSG cases done for morbid obesity at our hospital over 10 years to determine the distribution of gastric changes and the prevalence of Helicobacter pylori infection in these specimens. A retrospective study was conducted. All LSGs performed at Shifa International Hospital, Islamabad,Pakistan, from July 1, 2014, to June 30, 2024, were assessed. A total of 538 cases were included. Histopathology reports were reviewed for all these patients, and the histopathological diagnosis and the presence or absence of H. pylori infection were recorded. The mean age was 36.9 ± 11.4 years. There were 201 (37.4%) males. No abnormality was found in 105 (19.5%) cases. Gastritis was present in 433 (80.5%) cases. Intestinal metaplasia was present in eight (1.5%) cases in a background of gastritis. There were no cases of gastric atrophy or dysplasia. There was one case of submucosal lipoma (0.2%) and one case of gastrointestinal stromal tumor (GIST) (0.2%). Both cases were associated with gastritis. H. pylori infection was present in 140 (26.0%) cases. All of these were associated with gastritis. Among the gastritis cases, 319 (73.7%) had chronic gastritis, while 114 (26.3%) had both active and chronic gastritis. The severity of gastritis, as designated by the histopathologist in their report, was minimal in 24 (4.5%) cases, mild in 228 (42.4%), moderate in 176 (32.7%), and severe in five (0.9%). There was one case of granulomatous gastritis (non-caseating) (0.2%). There was no difference in the prevalence of gastritis or H. pylori infection based on age or gender. Histopathological examination of the LSG specimen revealed a very high prevalence of gastritis, with normal findings in less than a fifth of all cases. The prevalence of H. pylori infection (26.0%) is much higher in comparison to other studies. Routine histopathology of LSG specimens should continue to be performed in every case.

A Case of Immune Checkpoint Inhibitor-Related Gastritis and Severe Thrombocytopenia during Pembrolizumab and Axitinib Treatment

A Case of Immune Checkpoint Inhibitor-Related Gastritis and Severe Thrombocytopenia during Pembrolizumab and Axitinib Treatment.

A Case of Pemrolizumab-Associated Severe Gastritis Treated with Mycophenolate Mofetil

Immune checkpoint inhibitors have become a frequently used treatment in oncology practice. Although it has approved indications in many types of cancer, phase studies are ongoing in many types of cancer. Side effects due to the increasing use of immune checkpoint inhibitors have begun to be seen frequently. Cases of colitis, pancreatitis and hepatitis due to immune check point inhibitors have been reported very frequently; However, the number of gastritis cases is limited. Here, we presented a case of severe gastritis due to pembrolizumab in a patient with cholangiocellular carcinoma. When side effects develop due to immune check point inhibitors, infliximab and mycophenolate mofetil (MMF) treatments are used in steroid-refractory patients. In our patient, MMF treatment was started due to possible infectious processes due to a recent attack of cholangitis and the inability to remove the stones in the common bile duct. Response to MMF treatment was obtained after 3 months. We would like to state that MMF treatment is an option in cases that develop due to immune check point inhibitors. MMF treatment was used in a case of severe gastritis due to pembrolizumab, as it did not respond to steroid treatments. The patient responded after MMF treatment. We planned to present this rare side effect of pembrolizumab and the treatment strategies we applied in the development of side effects.

Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review.

Immune checkpoint inhibitors could restore immune surveillance to attack tumor through targeting CTLA-4, PD-1 or PD-L1, and have achieved huge success. However, immune-related adverse events (irAEs) have been attracting attention as their application is expanding. Gastritis is relatively rare as a subtype of irAEs, particularly severe gastritis. Guidelines on its clinical management still remain undefined due to limited data. Sintilimab is a PD-1 inhibitor approved in China. Here we offer a case of sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction. Conventional proton pump inhibitors and mucosal protective agents did not take effect, so glucocorticoid was chosen. This severe gastritis was successfully cured finally. Our report describing its clinical performances, endoscopic characteristics and treatments, could assist clinicians to better know this rare irAE.

A case of severe immune checkpoint inhibitor-related gastritis requiring differential diagnosis from scirrhous carcinoma

A case of severe immune checkpoint inhibitor-related gastritis requiring differential diagnosis from scirrhous carcinoma

S4319 A Case of Collagenous Gastritis: Insights into the Clinical Features and Therapeutic Considerations

S4319 A Case of Collagenous Gastritis: Insights into the Clinical Features and Therapeutic Considerations

S4126 A Case of Iron Pill-Induced Gastritis

S4126 A Case of Iron Pill-Induced Gastritis

Rapid Progression of Autoimmune Gastritis after Helicobacter pylori Eradication Therapy: A Case Report.

We herein report a case of autoimmune gastritis (AIG) with rapid progression after Helicobacter pylori eradication therapy. The patient's previous gastritis had followed the course of type B gastritis before eradication therapy for many years. Immediately after eradication, we diagnosed her with AIG and carefully followed changes in the endoscopic and histopathological findings and serum markers. All of these clinical findings showed significant atrophic progression in the corporal area for approximately three years. We concluded that H. pylori eradication therapy exacerbated AIG in this case.

A Case of Autoimmune Metaplastic Atrophic Gastritis with Concurrent Pernicious Anemia and Coombs-Negative Hemolysis

Pernicious anemia is an autoimmune disease characterized by atrophic gastritis and vitamin B12 deficiency. Concurrent hemolytic anemia has been described, however its prevalence and mechanism are not well understood. Herein, we present the case of a 40-year-old female who presented with abdominal pain, fatigue, and a 50-lb weight loss over four months. She was found to have macrocytic anemia, leukopenia, moderate neutropenia, and severe vitamin B12 deficiency. Further laboratory testing (indirect hyperbilirubinemia, low haptoglobin, increased lactate dehydrogenase, low reticulocyte index) implied the presence of intravascular hemolysis with a poor bone marrow response. Peripheral blood smear showed hypersegmented neutrophils consistent with megaloblastic anemia and schistocytes suggestive of hemolysis. Notably, the direct Coombs test was negative.The patient’s serum was positive for anti-intrinsic factor and anti-parietal cell antibodies. Esophagogastroduodenoscopy revealed H. Pylori-negative, metaplastic atrophic gastritis with no evidence of malignancy. Thus, a diagnosis of pernicious anemia was confirmed in addition to hemolytic anemia. She was treated with intramuscular cyanocobalamin, resulting in improvement of symptoms, cytopenias, and hemolytic markers. Hemolysis is a rare complication of vitamin B12 deficiency, and multifactorial anemia must always be considered.

Autoimmune gastritis with a gastric hamartomatous inverted polyp and two hyperplastic polyps: a case report

We report an unusual case of autoimmune gastritis (AIG) complicated with a submucosal tumor (SMT) and two pedunculated polyps in a 60-year-old man. The patient was admitted for epigastric distention, heartburn, and anorexia. Endoscopy showed an SMT in the fundus, two pedunculated polyps in the body, and markedly atrophic mucosa of the body and fundus. The SMT, measuring 20 mm in diameter, was resected by endoscopic submucosal dissection and histologically diagnosed as a gastric hamartomatous inverted polyp (GHIP), which is characterized by submucosal glandular proliferation, cystic dilatation, and calcification. The gland structures consisted of foveolar cells and pseudopyloric or mucous-neck cell types. The two pedunculated polyps that were resected by endoscopic mucosal resection were histologically diagnosed as hyperplastic polyps, which are characterized by hyperplastic foveolar glands with pseudopyloric or mucous-neck glands in the inflamed stroma in the mucosa, which consisted of almost the same types of lining cells as the GHIP in the fundus. Findings may indicate the relationship between GHIP, hyperplastic polyp, and AIG. We highlight considering GHIP as a differential diagnosis for an SMT in patients with AIG.

An unusual case of immune-related gastritis in one patient receiving toripalimab therapy.

PD-1 inhibitors contribute to immune response against malignancies. These drugs also result in serial side effects. Here the authors report a case of immune-related gastritis induced by PD-1 inhibitor. A female with metastatic lung cancer developed severe epigastric pain and acid reflux during treatment with toripalimab. She underwent several gastroscopies, which showed progressively worse gastritis. After discontinuing toripalimab, those symptoms were resolved. This rare report highlights gastritis associated with toripalimab, describes the symptoms and histology features and records the progression of this side effect and the corresponding treatment. Based on the improvement after toripalimab withdrawal, the authors believed that she had autoimmune gastritis caused by toripalimab. This case reminds us that correct diagnosis and proper management are critical to patients undergoing treatment with PD-1 inhibitors.

Reactivación de citomegalovirus en pacientes con gastritis inmunomediada

IntroductionReactivation of cytomegalovirus can complicate the evolution of patients with gastritis induced by immune checkpoint inhibitors. MethodsThe experience in our center is described and a review of the literature is performed. ResultsA case of severe gastritis induced by treatment with a programmed cell death receptor-1 (anti-PD1) inhibitor, associated with reactivation of cytomegalovirus (CMV) is described. In the systematic review, we identified 5 cases of immune-related gastritis associated with CMV reactivation. Ganciclovir treatment contributed to clinical improvement in most patients. ConclusionThe early identification of a CMV infection in patients with severe or refractory immune-related gastritis will allow the initiation of targeted treatment, and may avoid increasing immunosuppressive therapy.

Emphysematous gastritis on the post COVID-19 spectrum: A case report

Emphysematous gastritis is an uncommon, life-threatening form of gastritis caused by gas-forming microorganisms. It is frequently associated with diabetes mellitus, alcohol abuse, renal failure, recent abdominal surgery, gastroenteritis, long-term corticosteroid use, ingestion of corrosive agents, and nonsteroidal anti-inflammatory drug use. We report a case of emphysematous gastritis in a 42-year old COVID-recovered patient with no other known risk factors. The probable mechanism may be due to its immunosuppressive nature, which can be considered an independent risk factor for the development of deadly diseases. Medical management of emphysematous gastritis has gained popularity as a treatment option. Emergency gastrectomy is advised only for patients who continue to deteriorate after receiving the best medical care, develop an ulcer, a gastric infarction, or a perforation. We wish to demonstrate through our case study that conservative management of emphysematous gastritis can yield great results if done meticulously. We also aim to shed light on the potential for COVID-19 infections to be standalone immunocompromised states that facilitate lethal infections in susceptible individuals. However more research is required to definitively establish the same.